131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with variable differentiation status, which is distributed to a variety of organs. A high response rate and long...

Lead sponsor: Korea Cancer Center Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Hye Jin kang, M.D.

CONTACT

+82-2-970-1289 mdhyejin@gmail.com

Dong-Yeop Shin, M.D.

CONTACT

+82-2-970-1246 baramg@hanmail.net

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment28

Start dateOct 2011

Last updatedSep 5, 2012

Condition

Relapsed or Refractory Marginal Zone B-cell Lymphoma

Locations shown

Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2012Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions